S P E C I A L I S T I N S I G H T

I see it as critical to the future of healthcare .

The Life Sciences industry , along with healthcare more broadly , has entered one of the most exciting , and challenging , periods of its history and smart use of software is key to how it will delivering them efficiently and affordably is essential so that business models stay viable .

It ’ s why the industry is emerging as a trailblazer in using advanced technology . Targeted use of intelligent automation – harnessing AI / GenAI / Deep Learning – has immense potential to transform drug discovery and development . Up to now , pharma had a reputation for being behind the curve in its tech adoption . But now the industry is among the most directly innovative in its application of intelligent automation to transform key processes – particularly at the intersection of medical breakthrough development , regulatory approval and safety assurance . A recent global survey we conducted found that 60 % of biopharma companies are looking to extend their use of advanced technologies over the next 18 months .

As a technologically advanced company , ArisGlobal is actively helping pharma harness GenAI via tangible applications that transform the overall R & D IT processes across pharmacovigilance , regulatory and other associated domains .

The new accelerator for Life Sciences and for healthcare is the power we can derive from all of the rich data ( including standardised real-world data ) that ’ s now available to be analysed on the fly – as long as we have the technology to harness it reliably . For ArisGlobal , GenAI isn ’ t something that ’ s ‘ over there ’; we are working with our pharma customers to prioritise the most relevant focus areas to leverage GenAI .

As someone deeply involved in HealthTech and abreast of industry trends , what advice would you offer to individuals seeking to build a successful career in this rapidly evolving field , especially considering the importance of continuous learning and adaptation ?

There ’ s never been a more exciting time to enter this dynamic industry . Whereas other tech-advanced industries like financial services and retail are using advanced automation largely for cost efficiency , biopharma and healthcare are applying it to transform people ’ s lives .

Could you share some insights into the ArisGlobal ’ s current initiatives and projects aimed at leveraging next-gen technology to improve patient outcomes and streamline processes within the life sciences industry ?

We ’ ve been actively applying the latest AI and Machine Learning technology across the LifeSphere platform , along with leading discussions with global pharma about what ’ s possible . We recently launched a new global Life Sciences GenAI Council – a powerful peer group that ’ s pushing the boundaries of what ’ s possible with Generative AI across the Life Sciences R & D lifecycle .

Its members are leading representatives from Pharma , Academia and AI tech . The sessions combine blue-sky thinking with advanced technology expertise , to drive realworld problem-solving at a biopharma level .

The opportunities are broad and diverse , with large scope for career mobility and continuous learning , not least as new technologies and new approaches to delivering healthcare emerge . AI , Machine Learning and advanced data analytics are enabling important new discoveries and driving new approaches to treatment and new outcomes – and hope – for patients .

HealthTech and Life Sciences is highly collaborative , so there are substantial opportunities to explore different roles and functions right across science , tech , business and compliance .

With your leadership , ArisGlobal has made significant strides in advancing its strategy toward next-gen technology , including the launch of the LifeSphere SaaS offering . Can you provide some insights into the company ’ s vision for the future and how it plans to stay ahead in an increasingly competitive market ?

We ’ ve spearheaded innovation in Life Sciences for more than 35 years and are committed to pushing the envelope of what ’ s possible – specifically how advanced tech can help get more of the right

www . intelligenthealth . tech 49